3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Terminated
6
Withdrawn
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
49
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
14
Lymphoma, B-Cell, Marginal Zone
13
Lymphoma
9
Recurrence
7
Lymphoma, Non-Hodgkin
7
Neoplasms
6
Lymphoma, Mantle-Cell
5
Lymphoma, B-Cell
4
Neoplasms, Plasma Cell
3
Neoplasm, Residual
3
Lymphoma, T-Cell, Peripheral
3
Smoldering Multiple Myeloma
2
Leukemia, Plasma Cell
2
Hematologic Neoplasms
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Vitamin D Deficiency
1
Peripheral Nervous System Diseases
1
Paraproteinemias
1
Leukemia, Myeloid, Acute
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Hematologic Diseases
1
Heart Failure
1
Dendritic Cell Sarcoma, Interdigitating
1
Corneal Diseases
1
Cardiotoxicity
1
Blood Protein Disorders
1
Interventions
Rituximab
7
zanubrutinib
6
venetoclax
5
ibrutinib
3
Dexamethasone
3
pirtobrutinib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
Bendamustine Hydrochloride
2
obinutuzumab
1
Positron-Emission Tomography
1
Lenalidomide
1
Exercise
1
Diet
1
CT-P10
1
Bortezomib
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Waldenstrom Macroglobulinemia
×
Lenalidomide
×
Clear all
NCT03697356
2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2
Recruiting
54 enrolled